Loading clinical trials...
Loading clinical trials...
REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Reviva site
Philadelphia, Pennsylvania, United States
Reviva site
Bangalore, India
Reviva site
Chennai, India
Reviva site
Guntur, India
Reviva site
Jaipur, India
Reviva site
Kanpur, India
Reviva site
Lucknow, India
Reviva site
Mangalore, India
Reviva site
Johor Bahru, Malaysia
Reviva site
Kuala Lumpur, Malaysia
Start Date
December 1, 2011
Primary Completion Date
March 1, 2013
Completion Date
March 1, 2013
Last Updated
August 8, 2025
234
ACTUAL participants
RP5063
DRUG
placebo
DRUG
aripiprazole
DRUG
Lead Sponsor
Reviva Pharmaceuticals
NCT06740383
NCT07395206
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions